Identification of interferon-beta antibodies in a reference laboratory setting: Findings for 1144 consecutive sera

Prince, Harry E.; Lapé-Nixon, Mary; Audette, Carol D.; Horn, K. Van

doi:10.1016/j.jneuroim.2007.08.007

Cited by 13 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[18,19] Pharmacological forms of beta interferons differ in their immunogenicity; therefore, there is a different proportion of patients with elevated levels of antibodies for different formulations. [18,20] …”

Section: Discussionmentioning

confidence: 99%

“…[20–23] Importantly, the United States and Canadian authors demonstrated that the test reliability for the individual patient is better when one uses as the antigen the drug with which the patient has been treated. [20] All of the commercially available preparations of IFNb (at the time of patient recruitment these included: Rebif, Avonex i Betaferon) were used in this study.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The cross-reactivity of binding antibodies with different interferon beta formulations used as disease-modifying drugs in multiple sclerosis patients

et al. 2016

View full text Add to dashboard Cite

Interferon beta (IFNb) preparations are commonly used as first-line therapy in relapsing-remitting multiple sclerosis (RRMS). They are, however, characterized by limited efficacy, partly due to the formation of anti-IFNb antibodies in patients.In this pilot study, we assessed with the ELISA method the presence of the binding antibodies (BAbs) against interferon beta after 2 years of therapy with subcutaneous interferon beta 1a (Rebif) in 49 RRMS patients. Antibody levels were established again within 1 year after treatment withdrawal. We used 3 interferons that are commercially available for MS therapy, namely Avonex (Biogen Idec Limited), Rebif (Merck Serono), and Betaferon (Bayer Pharma AG), as antigens.BAbs reacting with Rebif were found in 24.4% to 55% of patients, depending on the units of their expression. The levels of anti-Rebif antibodies remained high in 8 patients and in 4 patients they dropped significantly. Strong correlations were obtained in all assays (anti-Rebif-anti-Avonex, anti-Rebif-anti-Betaferon, and anti-Betaferon-anti-Avonex) and the existence of cross-reactivity in the formation of antibodies against all the tested formulations of interferon beta was confirmed. The levels of BAbs remain significant in the clinical context, and their assessment is the first choice screening; however, methods of BAbs evaluation can be crucial for further decisions. More studies are needed to confirm our results; specifically it would be of interest to evaluate methods of neutralizing antibodies identification, as we only assessed the binding antibodies. Nevertheless, our results support the concept that in interferon nonresponders, that are positive for binding antibodies, switching the therapy to alternative disease-modifying agent (for example glatiramer acetate, fingolimod, or natalizumab) is justified, whereas the switch to another interferon formulation will probably be of no benefit.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

The cross-reactivity of binding antibodies with different interferon beta formulations used as disease-modifying drugs in multiple sclerosis patients

et al. 2016

View full text Add to dashboard Cite

show abstract

“…It has been discussed whether the measurements of BAbs provide information regarding neutralization of IFN-b response [18,19,37,38]. Measurement of BAbs with ELISA or Western blot was considered unsuitable for clinical use [39], although a capture ELISA may be used [18], and it was suggested that BAbs measurements of patients on IFN-b-1a could be performed as an alternative to NAbs analysis (measured by CPE bioassay) for samples with NAbs titres equal to or higher than 100 [38]. Because of the significant correlations for BAbs with both NAbs and MxAindexes, our results indicate that BAb measurements by the use of a capture ELISA provide useful results.…”

Section: Discussionmentioning

confidence: 99%

Correlation between anti‐interferon‐β binding and neutralizing antibodies in interferon‐β‐treated multiple sclerosis patients

Jensen

Sellebjerg

Søndergaard

et al. 2012

Euro J of Neurology

View full text Add to dashboard Cite

High correlation is demonstrated between the results obtained by the three methods, and we suggest the possibility of using ELISA measurements of BAbs to identify patients with high titres of anti-IFN-β antibodies that block the biological response to IFN-β. Ιn patients with low titres, we suggest to supplement ELISA with measurement of MX1 mRNA to establish whether the bioavailability of IFN-β is preserved.

show abstract

“…In a study of antibody testing at a commercial laboratory, a predictive relationship between BAb levels (N33 units) as measured by ELISA and high NAb titers (≥100 NU/mL) measured by CPE assay was found for patients receiving IFNβ-1a IM or IFNβ-1a SC, but not for those receiving IFNβ-1b [68]. The authors suggested that a one-step testing process (ie, BAb ELISA) may be sufficient for patients receiving IFNβ-1a with BAb levels N33 units.…”

Section: Assays For Measuring Antibodies Against Interferon Betamentioning

confidence: 99%

The implications of immunogenicity for protein-based multiple sclerosis therapies

Cohen

Oger

Gagnon³

et al. 2008

Journal of the Neurological Sciences

View full text Add to dashboard Cite

Identification of interferon-beta antibodies in a reference laboratory setting: Findings for 1144 consecutive sera

Cited by 13 publications

References 25 publications

The cross-reactivity of binding antibodies with different interferon beta formulations used as disease-modifying drugs in multiple sclerosis patients

The cross-reactivity of binding antibodies with different interferon beta formulations used as disease-modifying drugs in multiple sclerosis patients

Correlation between anti‐interferon‐β binding and neutralizing antibodies in interferon‐β‐treated multiple sclerosis patients

The implications of immunogenicity for protein-based multiple sclerosis therapies

Contact Info

Product

Resources

About